THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen (NASDAQ:AMGN) today announced it will present new data from osteoporosis studies of its investigational therapy, denosumab, at the 2008 American Society of Bone and Mineral Research (ASBMR) Annual Meeting that will be held in Montreal, Sept. 12-16, 2008. Additionally, data from the denosumab oncology program and the oncology therapeutics portfolio of marketed and pipeline products will be presented at the upcoming European Society of Medical Oncology (ESMO) Congress in Stockholm, Sweden, Sept. 12-16, 2008.
